Meeting
2023 ASCO Annual Meeting
Phase I trial of chimeric anti-GPC3 scFv-CD3ε engineered T cells (CT0180) in patients with advanced hepatocellular carcinoma.
Authors
Yi Zheng
Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
Yi Zheng , Qihan Fu , Qingwei Zhao , Lulu Liu , Zhou Tong , Hangyu Zhang , Peng Zhao , Weijia Fang , Xudong Zhu , Wanwan Gao , Miya Wang , Daijing Yuan , Huamao Wang , Zonghai Li , Tingbo Liang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer - Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT04756648
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4095)
DOI
10.1200/JCO.2023.41.16_suppl.4095
Abstract #
4095
Poster Bd #
416
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
A CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout (CB-010) in patients with relapsed/refractory B cell non-Hodgkin lymphoma (r/r B-NHL): Updated phase 1 results from the ANTLER trial.
First Author: Boyu Hu
Poster
2023 ASCO Annual Meeting
Safety and efficacy profile of a very low dose of MC-1-50 for treatment of r/r NHL.
First Author: Shiqi Li
Poster
2023 ASCO Annual Meeting
Examining safety and durable disease remission in R/R B-ALL after autologous CD19-directed CAR T cells produced by novel PRIMCAR manufacture platform.
First Author: Zhi Yang
Poster
2023 ASCO Gastrointestinal Cancers Symposium
A phase I study of GPC3 targeted CAR-T cell therapy in advanced GPC3-expressing hepatocellular carcinoma (HCC).
First Author: Changqing Xie